Asia-Pacific micro invasive glaucoma surgery (MIGS) devices market is projected to register a substantial CAGR of 29.1% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027
Market Segmentation:
Asia-Pacific Micro Invasive Glaucoma Surgery (MIGS) Devices Market, By Product (MIGS Stents, MIGS Shunts and Others), Target (Trabecular Meshwork, Suprachoroidal Space, Subconjunctival Filtration and Reducing Aqueous Production), Surgery Type (Glaucoma in Conjunction with Cataract and Stand-Alone Glaucoma), End User (Hospital Outpatient Departments (HOPD), Ophthalmology Clinics, Ambulatory Surgery Centers (ASCS) and Others), Distribution Channel (Direct Tender and Retail Sales), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific) – Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of the Asia-Pacific micro invasive glaucoma surgery (MIGS) devices market are:

• Government initiatives to increase awareness about prevention of blindness
• Increase in the geriatric population

Market Players:

The key market players for Asia-Pacific micro invasive glaucoma surgery (MIGS) devices market market are listed below:
• Glaukos Corporation
• Ivantis Inc.
• Allergan
• Ellex
• Alcon
• Johnson and Johnson Surgical Vision Inc. and Johnson and Johnson Vision Care Inc.(A subsidiary of Johnson and Johnson Inc.)
• MicroSurgical Technology (A Subsidiary of Halma plc)
• Molteno Ophthalmic Ltd.
• Santen Pharmaceutical